An interventional study of Laparoscopic OAGB and Laparoscopic RYGB in Obesity and Morbid, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2023, is one of 30 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 48th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–64 · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 12+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 368 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 110 across the 38 interventional studies, 175 across the 20 observational. Of the 36 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Obesity by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867354Assistance Publique - Hôpitaux de ParisPrevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients | 2027-03 |
| NCT06380426Assistance Publique - Hôpitaux de ParisA Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity | 2027-04-30 |
| NCT04893954Assistance Publique - Hôpitaux de ParisProspective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine. | 2027-07 |
| NCT06899997Assistance Publique - Hôpitaux de ParisStudy of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity with its consequences such as type 2 diabetes, high blood pressure, dyslipidemia, fatty liver disease, sleep apnea and cancers, remains a major healthcare problem worldwide. Bariatric surgery, combined with nutritional education and close monitoring, has been shown to be the most effective treatment for patients with morbid obesity resulting in significant and lasting weight loss and improvements in co-morbidities . With nearly 50000 procedures per year France ranks third in the world in terms of care for patients suffering from morbid (BMI ≥ 40 kg/m²) and severe (BMI 35-40 kg/m²) obesity.
In parallel with the significant increase in the number of patients operated on for obesity in the world, over the past two decades, significant development has been observed in the field of bariatric surgery with a decrease or even disappearance of some procedures and the appearance of others.
Performed for more than 40 years, the Roux-en-Y Gastric Bypass (RYGB) is a restrictive and malabsorptive procedure and currently is considered as gold standard procedure for the treatment of morbid obesity and its comorbidities. However, despite the good effectiveness (with an average Excess Weight Loss % (EWL%) of approximatively 70% at 2 years), RYGB is technically demanding procedure with learning curve requiring more than 100 cases and an overall complication rate ranging from 10% to 20% Introduced in 2001, one anastomosis gastric bypass (OAGB) is a modified gastric bypass that consists of a single gastrojejunal anastomosis between a long gastric pouch and a jejunal (biliopancreatic) omega loop. In Sept. 2019, taking into account the results from YOMEGA trial, the French High Authority for Health (Haute Autorité de Santé (HAS)) recommended to ban OAGB with 200 cm or longer BPL and urged to assess the efficacy and safety of OAGB with 150 cm BPL in a randomized controlled trial. Indeed, YOMEGA-2 trial is logical continuity of the YOMEGA trial.
The aim of this study is to assess weight loss efficiency and the nutritional safety of the OAGB-150 in comparison to a standard (RYGB).
The hypothesis of this study is that the OAGB with a 150 cm BPL could have the same efficacy on weight loss and nutritional complication rate in comparison to the RYGB at 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Laparoscopic OAGB will be performed with long and narrow gastric pouch (30cc) and 150 cm biliopancreatic limb
Procedure: Laparoscopic OAGB
This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Standard laparoscopic RYGB will be performed with a gastric pouch (30cc) and 150 cm antecolic Roux limb and a 50 cm biliopancreatic limb.
Procedure: Laparoscopic RYGB
It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
Also known as: One Anastomosis Gastric Bypass / Mini Gastric Bypass
A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
Also known as: Roux-en-Y Gastric Bypass
To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on weight loss (efficacy).
For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Efficacy: Weight loss according to Excess Weight Loss % (EWL%) calculated using the following formula: ((weight 2 years after surgery - initial weight) / (initial weight - ideal weight)) x 100. Ideal weight defined as the weight corresponding to a BMI = 25 kg/m². The assessment of the primary co-endpoint will be standardized between the sites.
Time frame: 2 years after the surgery
To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on nutritional complication rate (safety)
For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Safety: Nutritional complications defined by at least one vitamin deficiency (vit. B1 \< 66nmol/l or B12 \< 145pmol/l), malnutrition (albumin \< 30g/l), anemia (hemoglobin \< 10g/dl) or a combination of these. The assessment of the primary co-endpoint will be standardized between the sites.
Time frame: 2 years after the surgery
Measurement of albumin
Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l
Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of pre-albumin
Measurement of pre-albumin will explore the nutritional status of patients. Results will be expressed in g/l
Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of hemoglobin
Measurement of hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l
Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of calcium
Measurement of calcium will explore the nutritional status of patients. Results will be expressed in mmol/l
Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of ferritin
Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in μg/l
Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of iron
Measurement of iron will explore the nutritional status of patients. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of % of transferrin saturation
Measurement of % of transferrin saturation will explore the nutritional status of patients. Results will be expressed in %
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of zinc
Measurement of zinc will explore the nutritional status of patients. Results will be expressed in mmol/L
Time frame: Before surgery and 6, 12 months and 24 months after surgery
Measurement of vitamin A
Measurement of vitamin A will explore the nutritional status of patients. Results will be expressed in mmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of vitamin B1
Measurement of vitamin B1 will explore the nutritional status of patients. Results will be expressed in nmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of vitamin B9
Measurement of vitamin B9 will explore the nutritional status of patients. Results will be expressed in nmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of vitamin B12
Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of vitamin E
Measurement of vitamin E will explore the nutritional status of patients. Results will be expressed in mmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of vitamin D
Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of prothrombin rate
Measurement of prothrombin rate will explore the nutritional status of patients. Results will be expressed in %
Time frame: Before surgery and 6, 12 and 24 months after surgery
Measurement of the 24-hour steatorrhea rate
Measurement of the average number of stool will explore the nutritional status of patients. Results will be expressed in number of stool/day
Time frame: 6 month after surgery
Measurement of HbA1c
Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of fasting glycemia
Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of HDL
Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of LDL
Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of cholesterol
Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Measurement of triglycerides
Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Evaluation of antidiabetic drugs
Assessment of number of antidiabetic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
Time frame: Before surgery and 6, 12 and 24 months after surgery
Evaluation of antilipidemic drugs
Assessment of the number of antilipidemic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment
Time frame: Before surgery and 6, 12 and 24 months after surgery
Evaluation of antihypertensive drugs
Assessment of the number of antihypertensive medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
Time frame: Before surgery and 6, 12 and 24 months after surgery
Evaluation of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea
Evolution of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of the use or discontinuation of the use of Continuous Positive Airway Pressure machine
Time frame: Before surgery and 6, 12 and 24 months after surgery
Hospitalization length
The Length of stay (in days) is based on the number of days of hospitalization from surgery (day of surgery = D0) until the end of hospitalization.
Time frame: The last day of hospitalization
Number of patients readmitted
Number of patients readmitted within 30 days after surgery.
Time frame: 30 days after surgery
Occurrence of kidney stone
For each visit after the surgery, the presence or not of kidney stones will be documented and if applicable the treatment will be noted
Time frame: Within 2 years after surgery
Overall complications rate
Rate of medical and surgical (\> or = grade III) complications within 24 months after surgery using the Dindo-Clavien classification, described as : Grade I = Any deviation from the normal postoperative course. Grade II = Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III = Requiring surgical, endoscopic or radiological intervention, not under (Grade IIIa) or under general anesthesia (Grade IIIb) Grade IV = Life-threatening complication with single organ (Grade IVa) or Multiorgan dysfunction (Grade IVb) Grade V = Death of a patient.
Time frame: Within 24 months after surgery
Type of early complications
Type (medical or surgical) of early complications (within 30 days) for each procedure.
Time frame: Within 30 days after surgery
Severity of early complications
Severity of early complications (within 30 days) for each procedure according to the Dindo-Clavien classification
Time frame: Within 30 days after surgery
Type of late complications
Type (medical or surgical) of late complications (after 30 days) for each procedure.
Time frame: Within 2 years after surgery
Severity of late complications
Severity of late complications (after 30 days) for each procedure according to the Dindo-Clavien classification
Time frame: Within 2 years after surgery
Gastroesophageal reflux assessment
Evolution of gastroesophageal reflux will be assessed at each study visit, before and after surgery. This outcome will be expressed in terms of improvement, aggravation or onset.
Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery
Absolute weight loss assessment
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to absolute weight loss (aWL) in kg.
Time frame: 1, 3, 6, 12, 18 and 24 months after surgery
Excess Weight Loss percentage assessment
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to Excess Weight Loss percentage (EWL%), calculated using the following formula: ((weight at visit X - initial weight) / (initial weight - ideal weight)) X 100
Time frame: 1, 3, 6, 12, 18 and 24 months after surgery
Excess BMI Loss percentage assessment
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according Excess BMI Loss percentage (EBL%), according to the formula : ((BMI at visit X - initial BMI) / (initial BMI - ideal BMI)) X 100 with Ideal BMI = 25 kg/m²
Time frame: 1, 3, 6, 12, 18 and 24 months after surgery
Quality of life assessed with GIQLI questionnaire
This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 (highest score = 144) will be assigned. A high score defines a more favorable health state
Time frame: Before surgery and at 6, 12 and 24 months after surgery
Quality of life assessed with SF36 questionnaire
This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/tiredness, and general health perceptions. It also includes a single item that provides an indication of a perceived change in health
Time frame: Before surgery and at 6, 12 and 24 months after surgery
Quality of life assessed with Sigstad questionnaire
The Sigstad questionnaire allows the identification and diagnosis of postoperative dumping syndrome and early hypoglycaemia: a score \>7 suggests a dumping syndrome
Time frame: Before surgery and at 1, 3, 6, 12, 18 and 24 months after surgery
Body composition
Body composition level on a subsample of the total population: By impedancemetry : * Muscle mass index in kg/m2 * Non-fat mass index in kg/m2 * Fat mass index in kg/m2
Time frame: Before and 24 months after surgery.
Sarcopenia level
Sarcopenia level on a subsample of the total population will be assessed by Handgrip Strength
Time frame: Before and 24 months after surgery.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Oct 2028, 58 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 58 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →